Company History
Rxilient's journey began in 2021 with the establishment of three entities in Singapore, driven by a commitment to healthcare innovation and meeting evolving market needs.
-
2026
Expanded our commercial reach to Australia and Latin America
-
2025
Commerical launch of Lumirix® for the treatment for non-segmental vitiligo
-
2024
Expanded regional presence with new operations in Taiwan, Hong Kong, Macau, MENA
-
2023
Co-founded PharmaGend, a joint venture to manufacture pharmaceutical products in Singapore for global markets
-
2023
Established Excellmab, a joint venture to develop and commercialize Toripalimab across Southeast Asia
-
2023
Expanded regional presence with new operations in the Philippines, Thailand, and Vietnam
-
2022
Expanded geographic presence with operations established in Shanghai, Malaysia, and Indonesia
-
2021
Rxilient Established with Headquarters in Singapore
